Regado Biosciences secures $22 million via equity commitment agreement

Deal set with Domain, Novo Ventures, Frazier, Montreux Equity, Canaan

By Devika Patel

Knoxville, Tenn., Jan. 15 – Regado Biosciences, Inc. said it negotiated a $22 million equity commitment on Jan. 14, according to an 8-K filed Thursday with the Securities and Exchange Commission.

The company, who is merging with and into Tobira Therapeutics, Inc., will sell common shares at a per-share price equal to a minimum of Regado’s net cash at closing of the merger divided by the company’s fully diluted shares.

The investors include stockholders of Tobira, including Domain Associates, Novo Ventures, Frazier Healthcare, Montreux Equity Partners and Canaan Partners.

The biopharmaceutical company is based in Basking Ridge, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.